Clinical Trials Logo

Clinical Trial Summary

This study compared the performance of three automated immunoassays, Architect (Abbott), Immulite (Siemens) and Liaison (Diasorin), for Epstein-Barr virus (EBV) serology. Ninety-one serum samples collected in Amiens University Hospital were analyzed for the presence of Viral Capsid Antigen (VCA) IgG and IgM and Epstein-Barr Nuclear Antigen (EBNA) IgG. The agreement between the three assays was calculated for each marker individually and for determination of the EBV profile, based on interpretation of the combination of these three EBV markers.


Clinical Trial Description

This retrospective study was conducted on 91 samples collected between 2014 and 2015 for which EBV diagnosis was requested. The serological diagnosis of EBV infection was performed in the Amiens University Hospital virology laboratory (France). The median age of patients was 34 years (mean: 38 years, range: 3-82 year) with a sex ratio of 50%. Sixteen of the 91 samples concerned children (<15 years).

This study compared the performance of three automated immunoassays, Architect (Abbott), Immulite (Siemens) and Liaison (Diasorin), for Epstein-Barr virus (EBV) serology. Ninety-one serum samples collected in Amiens University Hospital were analyzed for the presence of Viral Capsid Antigen (VCA) IgG and IgM and Epstein-Barr Nuclear Antigen (EBNA) IgG. The agreement between the three assays was calculated for each marker individually and for determination of the EBV profile, based on interpretation of the combination of these three EBV markers. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03650231
Study type Observational
Source Centre Hospitalier Universitaire, Amiens
Contact
Status Completed
Phase
Start date January 1, 2015
Completion date October 29, 2017

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02878278 - Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect,Pharmacokinetics, Pharmacodynamics and EB Virus Activation Phase 2
Terminated NCT01948180 - Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma Phase 2
Completed NCT01923766 - Cytotoxic T Cells to Prevent Virus Infections Phase 1
Terminated NCT03699904 - Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial Phase 2
Recruiting NCT01011712 - The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Active, not recruiting NCT04645147 - Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection Phase 1
Terminated NCT02080416 - Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors Phase 0
Completed NCT02213068 - Belatacept 3 Month Post Transplant Conversion Study Phase 4
Recruiting NCT02779439 - Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation Phase 1
Not yet recruiting NCT05677178 - Response Prediction in EBV-HLH Using Metabonomics Analysis
Active, not recruiting NCT01945814 - Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) Phase 1
Recruiting NCT02007356 - A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System® Phase 2
Completed NCT03755440 - PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. Phase 2
Completed NCT03973723 - Plasma EBV DNA Monitoring in Post-treatment NPC Patients
Completed NCT02318030 - CNTRP POSITIVE Study